Filtros de búsqueda

Lista de obras de Antoni Ribas

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

artículo científico publicado en 2016

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

artículo científico publicado en 2016

A Phase I/II Trial Testing Immunization of Hepatocellular Carcinoma Patients with Dendritic Cells Pulsed with Four -Fetoprotein Peptides

artículo científico publicado en 2006

A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265).

artículo científico publicado en 2015

A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab

artículo científico publicado en 2018

A beta-camera integrated with a microfluidic chip for radioassays based on real-time imaging of glycolysis in small cell populations

artículo científico publicado en 2011

A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells.

artículo científico publicado en 2011

A kinetic investigation of interacting, stimulated T cells identifies conditions for rapid functional enhancement, minimal phenotype differentiation, and improved adoptive cell transfer tumor eradication

artículo científico publicado en 2018

A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma

artículo científico publicado en 2011

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition

artículo científico publicado en 2014

A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma

artículo científico publicado en 2010

A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.

artículo científico publicado en 2010

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors

artículo científico publicado en 2016

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma.

artículo científico publicado en 2015

A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States

artículo científico publicado en 2014

A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".

artículo científico publicado en 2008

ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways.

artículo científico publicado en 2017

Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome

article

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

artículo científico publicado en 2015

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

artículo científico publicado en 2013

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

artículo científico publicado en 2015

Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma

artículo científico publicado en 2008

Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival

artículo científico publicado en 2014

Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma

artículo científico publicado en 2014

Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology

scientific article published on 21 March 2019

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations.

artículo científico publicado en 2018

Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells

artículo científico publicado en 2013

An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy

artículo científico publicado en 2015

Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response

scientific article published on 01 June 2019

Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers

artículo científico publicado en 2018

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

artículo científico publicado en 2011

Anti-PD-1 antibody treatment for melanoma

artículo científico publicado en 2018

Anti-PD-1 therapy in melanoma

artículo científico

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

artículo científico publicado en 2014

Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain

artículo científico publicado en 2008

Antibody blockade of semaphorin 4D breaks down barriers to enhance tumoricidal immune infiltration and supports rational immunotherapy combinations

artículo científico publicado en 2015

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

artículo científico publicado en 2015

Antigen Presentation Keeps Trending in Immunotherapy Resistance.

artículo científico publicado en 2018

Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.

artículo científico publicado en 2011

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

artículo científico publicado en 2005

Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma

artículo científico publicado en 2014

Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines

artículo científico publicado en 2012

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

artículo científico publicado en 2018

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials

artículo científico publicado en 2020

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

artículo científico publicado en 2016

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.

artículo científico publicado en 2018

Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib.

artículo científico publicado en 2017

Autoantibody landscape in patients with advanced prostate cancer

scientific article published on 23 September 2020

Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition

artículo científico publicado en 2019

BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy

artículo científico publicado en 2012

BRAF targeted therapy changes the treatment paradigm in melanoma

artículo científico publicado en 2011

BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors

artículo científico publicado en 2012

BRAF-targeted therapy and immune responses to melanoma

artículo científico publicado en 2013

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

article

Bilateral Subfoveal Neurosensory Retinal Detachment Associated With MEK Inhibitor Use for Metastatic Cancer

Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma.

artículo científico publicado en 2014

Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice

artículo científico publicado en 2005

CANCER IMMUNOLOGY. The "cancer immunogram".

artículo científico publicado en 2016

CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model

scientific article published on July 2008

CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893.

artículo científico publicado en 2010

COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors

artículo científico publicado en 2013

CRAF R391W is a melanoma driver oncogene

artículo científico publicado en 2016

CTLA4 blockade broadens the peripheral T-cell receptor repertoire

artículo científico publicado en 2014

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma

artículo científico publicado en 2009

CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans

artículo científico publicado en 2011

Cancer Research in the 21st Century

artículo científico publicado en 2016

Cancer immunotherapy using checkpoint blockade.

artículo científico publicado en 2018

Cancer immunotherapy using gene-modified dendritic cells.

artículo científico publicado en 2002

Cancer therapy: Tumours switch to resist

artículo científico publicado en 2012

Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products

artículo científico publicado en 2018

Classifying Cancers Based on T-cell Infiltration and PD-L1.

artículo científico publicado en 2015

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

artículo científico publicado en 2010

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

artículo científico publicado en 2017

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

artículo científico publicado en 2016

Combination cancer immunotherapies tailored to the tumour microenvironment

artículo científico publicado en 2015

Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.

artículo científico publicado en 2015

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

artículo científico publicado en 2015

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study

artículo científico publicado en 2014

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy

artículo científico publicado en 2016

Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations

artículo científico publicado en 2011

Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition

artículo científico publicado en 2011

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

artículo científico publicado en 2014

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

artículo científico publicado en 2019

Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i

artículo científico publicado en 2020

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma

artículo científico publicado en 2015

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

artículo científico publicado en 2014

Combining cancer immunotherapy and targeted therapy

artículo científico publicado en 2013

Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges

artículo científico publicado en 2014

Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?

artículo científico publicado en 2016

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, o

article

Consensus nomenclature for CD8(+) T cell phenotypes in cancer

artículo científico publicado en 2015

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

scientific article published on 08 September 2020

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

artículo científico publicado en 2020

Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial

artículo científico publicado en 2020

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

scientific article published on 01 December 2018

Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA.

artículo científico publicado en 2014

Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.

artículo científico publicado en 2016

Current developments in cancer vaccines and cellular immunotherapy

artículo científico publicado en 2003

Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors

artículo científico publicado en 2010

Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors

artículo científico publicado en 2016

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

artículo científico publicado en 2015

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

artículo científico publicado en 2019

Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway

artículo científico publicado en 2011

Defining the critical hurdles in cancer immunotherapy

artículo científico publicado en 2011

Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays

artículo científico publicado en 2006

Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma

artículo científico publicado en 2009

Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models.

artículo científico publicado en 2013

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

artículo científico publicado en 2008

Detection of antibody therapy-induced anti-tumor immune responses using anti-CD8 immuno-pet.

artículo científico publicado en 2015

Determinant spreading and tumor responses after peptide-based cancer immunotherapy

artículo científico publicado en 2003

Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.

artículo científico publicado en 2003

Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer

scientific article published on 05 September 2019

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.

artículo científico publicado en 2018

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

artículo científico publicado en 2010

Disparities in Cancer Prevention in the COVID-19 Era

scientific article published on 17 September 2020

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes.

artículo científico publicado en 2014

Do we need a different set of response assessment criteria for tumor immunotherapy?

artículo científico publicado en 2009

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

artículo científico publicado en 2017

Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Anti-Tumor T-cell Immunity

artículo científico publicado en 2020

Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib

artículo científico publicado en 2019

Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations

artículo científico publicado en 2013

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma

artículo científico publicado en 2014

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma

artículo científico publicado en 2014

Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL)

article

Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology

artículo científico publicado en 2009

Endocrinopathies with use of cancer immunotherapies

artículo científico publicado en 2017

Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824.

artículo científico publicado en 2009

Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells

artículo científico publicado en 2004

Epigenetic Suppression of Transgenic T-cell Receptor Expression via Gamma-Retroviral Vector Methylation in Adoptive Cell Transfer Therapy

artículo científico publicado en 2020

ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors

artículo científico publicado en 2015

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

artículo científico publicado en 2015

Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

artículo científico publicado en 2015

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

artículo científico publicado en 2016

Excluding T Cells: Is β-Catenin the Full Story?

artículo científico publicado en 2015

Exosomes as a predictor tool of acquired resistance to melanoma treatment

artículo científico publicado en 2014

Expanded access programmes: patient interests versus clinical trial integrity

artículo científico publicado en 2014

Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function

artículo científico publicado en 2014

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma

artículo científico publicado en 2019

Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma

artículo científico publicado en 2013

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials

artículo científico publicado en 2016

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

artículo científico publicado en 2017

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

artículo científico publicado en 2017

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

artículo científico publicado en 2019

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".

artículo científico publicado en 2013

Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010"

artículo científico publicado en 2011

Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".

artículo científico publicado en 2012

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

artículo científico publicado en 2014

Gauging the Long-Term Benefits of Ipilimumab in Melanoma.

artículo científico publicado en 2015

Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib

artículo científico publicado en 2017

Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses

scientific article published on 01 October 2019

Genetic basis for clinical response to CTLA-4 blockade in melanoma

artículo científico publicado en 2014

Genetic mechanisms of immune evasion in colorectal cancer

artículo científico publicado en 2018

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600-mutated Metastatic Melanoma

scientific article published on 01 March 2019

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

artículo científico publicado en 2016

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

artículo científico publicado en 2017

Global alteration of T-lymphocyte metabolism by PD-L1 checkpoint involves a block of de novo nucleoside phosphate synthesis

scientific article published on 26 November 2019

Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death

artículo científico publicado en 2012

HMGB1 mediates endogenous TLR2 activation and brain tumor regression

artículo científico publicado en 2009

HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice

artículo científico publicado en 2014

Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma

artículo científico publicado en 2015

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma

artículo científico publicado en 2018

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma

artículo científico publicado en 2016

Hepatotoxicity with combination of vemurafenib and ipilimumab

artículo científico publicado en 2013

High frequency of brain metastases after adjuvant therapy for high-risk melanoma

artículo científico publicado en 2017

High response rate to PD-1 blockade in desmoplastic melanomas

artículo científico publicado en 2018

Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting

artículo científico publicado en 2013

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

artículo científico publicado en 2013

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

artículo científico publicado en 2015

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

artículo científico publicado en 2013

Human Antigen-Specific Regulatory T Cells Generated by T Cell Receptor Gene Transfer ⬇️

artículo científico publicado el 22 de julio de 2010

Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses

artículo científico publicado en 2004

IL-32γ potentiates tumor immunity in melanoma

artículo científico publicado en 2020

IND-enabling studies for a clinical trial to genetically program a persistent cancer-targeted immune system

artículo científico publicado en 2018

Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab

artículo científico publicado en 2010

Immune rejection in a humanized model of murine prostate cancer

artículo científico publicado en 2010

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

artículo científico publicado en 2016

Immunomodulation by imiquimod in patients with high-risk primary melanoma

artículo científico publicado en 2011

Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).

artículo científico publicado en 2006

Immunosensitization with a Bcl-2 small molecule inhibitor

artículo científico publicado en 2008

Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines

artículo científico publicado en 2002

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

artículo científico publicado en 2018

Immunotherapy Resistance by Inflammation-Induced Dedifferentiation

article published in 2018

Immunotherapy of hepatocellular carcinoma

artículo científico publicado en 2002

Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma

artículo científico publicado en 2013

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM

scientific article published on 16 August 2019

Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials

artículo científico publicado en 2020

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma

artículo científico publicado en 2015

Improved overall survival in melanoma with combined dabrafenib and trametinib

artículo científico publicado en 2015

Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients

artículo científico publicado en 2014

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

artículo científico publicado en 2011

Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma

artículo científico publicado en 2016

Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy

artículo científico publicado en 2013

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

artículo científico publicado en 2010

Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition

artículo científico publicado en 2015

Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure.

artículo científico publicado en 2015

Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma

scientific article published on 17 November 2020

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

scientific article published on 01 December 2019

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.

artículo científico publicado en 2017

Interferon alfa in the postsurgical management of high-risk melanoma: is it worth it?

artículo científico publicado en 2009

Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3.

artículo científico publicado en 2015

Interleukin 32 expression in human melanoma

artículo científico publicado en 2019

Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial

artículo científico publicado en 2011

Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade

artículo científico publicado en 2009

Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells

artículo científico publicado en 2004

Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules

article published in the Proceedings of the National Academy of Sciences of the United States of America

JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma

artículo científico publicado en 2016

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma

scientific article published on 01 December 2020

Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction

artículo científico publicado en 2020

Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses

artículo científico publicado en 2010

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer

artículo científico publicado en 2018

Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines

artículo científico publicado en 2007

Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab

artículo científico publicado en 2015

Long-Term Follow-Up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients With Advanced Melanoma: KEYNOTE-029 Part 1B

scientific article published on 30 June 2020

Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression

artículo científico publicado en 2015

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials

scientific article published on 01 January 2020

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

artículo científico publicado en 2020

Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence

artículo científico publicado en 2014

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

artículo científico publicado en 2014

MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy

artículo científico publicado en 2017

MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor

artículo científico publicado en 2017

MITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells.

artículo científico publicado en 2015

Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.

artículo científico publicado en 2012

Mechanisms of Resistance to PD-1 and PD-L1 Blockade.

artículo científico publicado en 2018

Meeting report from the 2011 International Melanoma Congress, Tampa, Florida.

artículo científico publicado en 2011

Meeting report from the Third Global Workshop on Melanoma.

artículo científico publicado en 2010

Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008

Melanoma

2015 article in Nature Reviews Disease Primers

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

artículo científico publicado en 2016

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

artículo científico publicado en 2012

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

artículo científico publicado en 2010

Metastatic melanoma to the kidney presenting with renal vein tumor thrombus

artículo científico publicado en 2007

Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials

Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells.

artículo científico publicado en 2009

Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma

artículo científico publicado en 2010

Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line

scientific article published on 11 May 2020

Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress.

artículo científico publicado en 2018

Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma

artículo científico publicado en 2010

Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy

artículo científico publicado en 2013

Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens

scientific article published in 2023

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

artículo científico publicado en 2016

NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain

artículo científico publicado en 2006

Natural killer T cells in advanced melanoma patients treated with tremelimumab

artículo científico publicado en 2013

Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells

artículo científico publicado en 2005

Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy

scientific article published on 08 March 2023

New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone

artículo científico publicado en 2017

New challenges in endpoints for drug development in advanced melanoma

artículo científico publicado en 2011

New drug targets in metastatic melanoma

artículo científico

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

artículo científico publicado en 2015

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

artículo científico publicado en 2018

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

artículo científico publicado en 2017

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial

artículo científico publicado en 2018

Overcoming barriers to programming a therapeutic cellular immune response to fight melanoma

artículo científico publicado en 2010

Overcoming genetically-based resistance mechanisms to PD-1 blockade

artículo científico publicado en 2020

PAK4 inhibition improves PD-1 blockade immunotherapy

artículo científico publicado en 2019

PD-1 Blockade Expands Intratumoral Memory T Cells

artículo científico publicado en 2016

PD-1 blockade induces responses by inhibiting adaptive immune resistance

artículo científico publicado en 2014

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

scientific article published on 07 December 2020

PET imaging of cancer immunotherapy.

artículo científico publicado en 2008

PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody

artículo científico publicado en 2013

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

artículo científico publicado en 2011

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy

artículo científico publicado en 2018

Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC).

artículo científico publicado en 2014

Pembrolizumab plus pegylated interferon alfa-2b or ipilimumab for advanced melanoma or renal cell carcinoma: dose-finding results from the phase 1b KEYNOTE-029 study

artículo científico publicado en 2018

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

artículo científico publicado en 2015

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

artículo científico publicado en 2017

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

scientific article published on 22 July 2019

Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist

artículo científico publicado en 2020

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

artículo científico publicado en 2013

Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.

artículo científico publicado en 2014

Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

artículo científico publicado en 2009

Phase I/II trial of tremelimumab in patients with metastatic melanoma

article

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

artículo científico publicado en 2012

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma

artículo científico publicado en 2013

Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.

artículo científico publicado en 2012

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

artículo científico publicado en 2013

Phenotypic heterogeneity and evolution of melanoma cells associated with targeted therapy resistance.

artículo científico publicado en 2019

Polymer nanofiber-embedded microchips for detection, isolation, and molecular analysis of single circulating melanoma cells

artículo científico publicado en 2013

Precise T cell recognition programs designed by transcriptionally linking multiple receptors

artículo científico publicado en 2020

Prediction of SARS-CoV-2 epitopes across 9360 HLA class I alleles

artículo científico publicado en 2020

Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors

artículo científico publicado en 2012

Preparation of peptide-MHC and T-cell receptor dextramers by biotinylated dextran doping

artículo científico publicado en 2017

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

artículo científico publicado en 2016

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

artículo científico publicado en 2017

Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited

artículo científico publicado en 2020

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma

artículo científico publicado en 2016

Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

scientific article published on 01 August 2019

Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen

artículo científico publicado en 2008

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

artículo científico publicado en 2012

Raman-guided subcellular pharmaco-metabolomics for metastatic melanoma cells

scientific article published on 24 September 2020

Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation

artículo científico publicado en 2017

Reply to K.S. Wilson et al

scientific article published on 01 August 2013

Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis

artículo científico publicado en 2014

Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells

artículo científico publicado en 2016

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.

artículo científico publicado en 2011

Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy

artículo científico publicado en 2004

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

artículo científico publicado en 2018

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

artículo científico publicado en 2013

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

artículo científico publicado en 2014

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion

artículo científico publicado en 2012

Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes.

artículo científico publicado en 2018

Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood

scientific article published on 01 September 2019

Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma

artículo científico publicado en 2013

Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance

artículo científico publicado en 2017

Single-cell analysis tools for drug discovery and development

artículo científico publicado en 2016

SnapShot: Immune Checkpoint Inhibitors.

artículo científico publicado en 2017

Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group

artículo científico publicado en 2014

Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer.

artículo científico publicado en 2007

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.

artículo científico

Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma

artículo científico publicado en 2004

Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma.

artículo científico publicado en 2007

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

artículo científico publicado en 2012

Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019

scientific article published on 13 March 2020

Survival of patients with advanced metastatic melanoma: The impact of novel therapies

artículo científico

Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.

artículo científico publicado en 2017

T cell antigen discovery via signaling and antigen-presenting bifunctional receptors

artículo científico publicado en 2019

T cell antigen discovery via trogocytosis

artículo científico publicado en 2019

T-cell immunotherapy: looking forward

artículo científico publicado en 2014

T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer.

artículo científico publicado en 2003

T-cell responses to survivin in cancer patients undergoing radiation therapy

scientific article published on August 2008

Targeted agents and immunotherapies: optimizing outcomes in melanoma

artículo científico publicado en 2017

Targeted therapies to improve tumor immunotherapy

artículo científico publicado en 2008

Targeting oncogenic drivers and the immune system in melanoma.

artículo científico publicado en 2012

The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms

artículo científico publicado en 2012

The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics

artículo científico publicado en 2014

The efficacy of anti-PD-1 agents in acral and mucosal melanoma

artículo científico publicado en 2016

The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade

artículo científico publicado en 2014

The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy

artículo científico publicado en 2010

The new era of adjuvant therapies for melanoma

scientific article published on 01 September 2018

The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations

artículo científico publicado en 2010

The state of melanoma: challenges and opportunities

artículo científico publicado en 2016

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials

artículo científico publicado en 2017

Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer

artículo científico publicado en 2007

Trying for a BRAF Slam Dunk

artículo científico publicado en 2020

Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer

artículo científico publicado en 2019

Tumor Immunotherapy Directed at PD-1

artículo científico publicado en 2012

Tumour-intrinsic resistance to immune checkpoint blockade

scientific article published on 30 September 2019

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction

artículo científico publicado en 2015

Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma

artículo científico publicado en 2020

Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAFV600- mutated melanoma (BRIM7).

artículo científico publicado en 2014

Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.

artículo científico publicado en 2017

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

artículo científico publicado en 2012

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)

article published in 2015

sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

artículo científico publicado en 2016

siRNA Knockdown of Ribonucleotide Reductase Inhibits Melanoma Cell Line Proliferation Alone or Synergistically with Temozolomide ⬇️

artículo científico publicado el 14 de octubre de 2010

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda